RSCM
FSTX

Rock Springs Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Rock Springs Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-751,889
Closed -$4.75M – 123
2022
Q4 		$4.75M Hold
751,889
– – 0.11% 88
2022
Q3 		$3.85M Hold
751,889
– – 0.1% 100
2022
Q2 		$4.71M Hold
751,889
– – 0.14% 95
2022
Q1 		$2.67M Hold
751,889
– – 0.07% 122
2021
Q4 		$3.77M Sell
751,889
-302,343
-29% -$1.82M 0.09% 122
2021
Q3 		$7.72M Hold
1,054,232
– – 0.16% 117
2021
Q2 		$9.06M Buy
+1,054,232
New +$8.99M 0.18% 120

Rock Springs Capital Management's FSTX Position: Q1 2023 in Review

Rock Springs Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 751,889 shares — an estimated $4.75M sold.

Rock Springs Capital Management first reported a position in FSTX in Q2 2021 and held it in 7 quarters. The position peaked at $9.06M in Q2 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Rock Springs Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Rock Springs Capital Management sold 751,889 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4.75M.
  • Rock Springs Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
  • Rock Springs Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $9.06M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.